In patients with nasopharyngeal carcinoma who received induction-concurrent (chemo)radiotherapy, persistent Epstein-Barr virus (EBV) DNA positivity or its resurgence during treatment was ...

for the first-line treatment of adults with recurrent or metastatic nonkeratinizing nasopharyngeal carcinoma (NPC); or as a single agent, for the treatment of adults with metastatic ...

The FDA has approved penpulimab-kcqx with chemotherapy and as a single agent for some patients with nasopharyngeal carcinoma. The United States Food and Drug Administration (FDA) has approved ...

in combination with cisplatin or carboplatin and gemcitabine as first-line treatment for adults with certain types of nasopharyngeal carcinoma (NPC), and as a single agent for certain patients ...

Dr. Patrick Ling, MD, Dip Sport Med, discusses hip bursitis in athletes. RFK Jr. Calls Out King Abdullah: ‘They’ve Cut Us Off’ Shark Tank's Kevin O'Leary sends strong message on Social ...

KUALA LUMPUR: Bursa Malaysia and its subsidiaries will be closed on May 12, in conjunction with the Wesak Day public holiday. “Bursa Malaysia and its subsidiaries will resume operations on May ...

Bursa Malaysia opened higher today, following Wall Street’s upbeat performance driven by falling US Treasury yields and the White House’s easing tariff rhetoric, including a planned rollback ...

Approval of penpulimab-kcqx marks the company’s US regulatory debut and introduces a new immunotherapy option for advanced nasopharyngeal carcinoma. The FDA has approved Akeso’s penpulimab-kcqx, a ...

The antibody is to treat adult recurrent or metastatic non-keratinising nasopharyngeal carcinoma (NPC) in conjunction with cisplatin or carboplatin and gemcitabine as a first-line treatment.

The FDA approved the PD-1 inhibitor penpulimab, with two indications, for treating non-keratinizing nasopharyngeal carcinoma (NPC) in adults. No trade name was indicated for the drug. The first ...

The Securities Commission Malaysia and Bursa Malaysia this morning reassured investors that the integrity of Malaysia’s capital market remains intact following reports of unauthorised access and ...